BAJFINANCE vs SUNPHARMA: Stock Comparison
BAJAJ FINANCE is the larger company by market capitalisation. BAJAJ FINANCE shows a lower P/E, a higher ROE and faster revenue growth, while SUN PHARMACEUTICAL IND L shows a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BAJFINANCE leads 8; SUNPHARMA leads 4 of 12
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BAJFINANCE | SUNPHARMA |
|---|---|---|
| Sector | Financial Services | Healthcare |
| Industry | Non Banking Financial Company (NBFC) | Pharmaceuticals |
Price
| Metric | BAJFINANCE | SUNPHARMA |
|---|---|---|
| Live Price | ₹960 | ₹1,760 |
| Day Change | 0.42% | 0.01% |
| Volume | 76.84 L | 13.46 L |
| 52-Week High | ₹1,176.4 | ₹2,046.9 |
| 52-Week Low | ₹787.9 | ₹1,583.7 |
| Distance from 52W High | -18.4% | -14.02% |
Valuation
| Metric | BAJFINANCE | SUNPHARMA |
|---|---|---|
| Market Cap | ₹5.97 L Cr | ₹4.22 L Cr |
| P/E Ratio | 29.37x | 34.85x |
| P/B Ratio | 5.23x | 5.04x |
| EPS | ₹9.61 | ₹12.06 |
| Book Value | ₹187.9 | ₹349.6 |
| Dividend Yield | 0.63% | 0.91% |
Growth
| Metric | BAJFINANCE | SUNPHARMA |
|---|---|---|
| Revenue Growth (TTM YoY) | 26.8% | 12.8% |
| EPS Growth (TTM YoY) | 21.4% | 25.6% |
| Qtr Sales Growth | 16.98% | 4.71% |
| Qtr Profit Growth | 13.75% | 7.07% |
Profitability & Leverage
Debt-to-equity is shown for reference only — it is not a like-for-like metric for banks and financials.| Metric | BAJFINANCE | SUNPHARMA |
|---|---|---|
| ROE | 16.53% | 11.76% |
| ROCE | 14.28% | 9.6% |
| Net Margin | 37.88% | 18.56% |
| Operating Margin | 66% | 22.81% |
| Debt to Equity | 1.46x | 0.6x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BAJFINANCE | SUNPHARMA |
|---|---|---|
| Promoter Holding | 54.67%▼ 0.03 pp | 54.48% |
| FII Holding | 20.21%▼ 1.12 pp | 14.53%▼ 1.4 pp |
| DII Holding | 16.4%▲ 1.22 pp | 22.18%▲ 1.07 pp |
| Public Holding | 8.64%▼ 0.07 pp | 8.81%▲ 0.33 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BAJAJ FINANCE and SUN PHARMACEUTICAL IND L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.